Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-02-2013 | Article

A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain–Barré syndrome

Authors: R. Louwen, D. Horst-Kreft, A. G. de Boer, L. van der Graaf, G. de Knegt, M. Hamersma, A. P. Heikema, A. R. Timms, B. C. Jacobs, J. A. Wagenaar, H. P. Endtz, J. van der Oost, J. M. Wells, E. E. S. Nieuwenhuis, A. H. M. van Vliet, P. T. J. Willemsen, P. van Baarlen, A. van Belkum

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2013

Abstract

Guillain–Barré syndrome (GBS) is a post-infectious disease in which the human peripheral nervous system is affected after infection by specific pathogenic bacteria, including Campylobacter jejuni. GBS is suggested to be provoked by molecular mimicry between sialylated lipooligosaccharide (LOS) structures on the cell envelope of these bacteria and ganglioside epitopes on the human peripheral nerves, resulting in autoimmune-driven nerve destruction. Earlier, the C. jejuni sialyltransferase (Cst-II) was found to be linked to GBS and demonstrated to be involved in the biosynthesis of the ganglioside-like LOS structures. Apart from a role in pathogenicity, we report here that Cst-II-generated ganglioside-like LOS structures confer efficient bacteriophage resistance in C. jejuni. By bioinformatic analysis, it is revealed that the presence of sialyltransferases in C. jejuni and other potential GBS-related pathogens correlated significantly with the apparent degeneration of an alternative anti-virus system: type II Clusters of Regularly Interspaced Short Palindromic Repeat and associated genes (CRISPR-Cas). Molecular analysis of the C. jejuni CRISPR-Cas system confirmed the bioinformatic investigation. CRISPR degeneration and mutations in the cas genes cas2, cas1 and csn1 were found to correlate with Cst-II sialyltransferase presence (p < 0.0001). Remarkably, type II CRISPR-Cas systems are mainly found in mammalian pathogens. To study the potential involvement of this system in pathogenicity, we inactivated the type II CRISPR-Cas marker gene csn1, which effectively reduced virulence in primarily cst-II-positive C. jejuni isolates. Our findings indicate a novel link between viral defence, virulence and GBS in a pathogenic bacterium.

Available only for authorised users

Guerrant RL, Hughes JM, Lima NL, Crane J (1990) Diarrhea in developed and developing countries: magnitude, special settings, and etiologies. Rev Infect Dis 12(Suppl 1):S41–S50PubMedCrossRef

Stephens DS (2009) Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 27(Suppl 2):B71–B77PubMedCrossRef

Harrison LH, Simonsen V, Waldman EA (2008) Emergence and disappearance of a virulent clone of Haemophilus influenzae biogroup aegyptius, cause of Brazilian purpuric fever. Clin Microbiol Rev 21(4):594–605PubMedCrossRef

Nakwan N, Nakwan N, Atta T, Chokephaibulkit K (2009) Neonatal pasteurellosis: a review of reported cases. Arch Dis Child Fetal Neonatal Ed 94(5):F373–F376PubMedCrossRef

Severi E, Hood DW, Thomas GH (2007) Sialic acid utilization by bacterial pathogens. Microbiology 153(Pt 9):2817–2822PubMedCrossRef

Guerry P, Ewing CP, Hickey TE, Prendergast MM, Moran AP (2000) Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni. Infect Immun 68(12):6656–6662PubMedCrossRef

Fox KL, Cox AD, Gilbert M, Wakarchuk WW, Li J, Makepeace K, Richards JC, Moxon ER, Hood DW (2006) Identification of a bifunctional lipopolysaccharide sialyltransferase in Haemophilus influenzae: incorporation of disialic acid. J Biol Chem 281(52):40024–40032PubMedCrossRef

Tatum FM, Tabatabai LB, Briggs RE (2009) Sialic acid uptake is necessary for virulence of Pasteurella multocida in turkeys. Microb Pathog 46(6):337–344PubMedCrossRef

Habib I, Louwen R, Uyttendaele M, Houf K, Vandenberg O, Nieuwenhuis EE, Miller WG, van Belkum A, De Zutter L (2009) Correlation between genotypic diversity, lipooligosaccharide gene locus class variation, and caco-2 cell invasion potential of Campylobacter jejuni isolates from chicken meat and humans: contribution to virulotyping. Appl Environ Microbiol 75(13):4277–4288PubMedCrossRef

10.

Louwen R, Heikema A, van Belkum A, Ott A, Gilbert M, Ang W, Endtz HP, Bergman MP, Nieuwenhuis EE (2008) The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. Infect Immun 76(10):4431–4438PubMedCrossRef

11.

Perera VN, Nachamkin I, Ung H, Patterson JH, McConville MJ, Coloe PJ, Fry BN (2007) Molecular mimicry in Campylobacter jejuni: role of the lipo-oligosaccharide core oligosaccharide in inducing anti-ganglioside antibodies. FEMS Immunol Med Microbiol 50(1):27–36PubMedCrossRef

12.

Unkmeir A, Kämmerer U, Stade A, Hübner C, Haller S, Kolb-Mäurer A, Frosch M, Dietrich G (2002) Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 70(5):2454–2462PubMedCrossRef

13.

Hammerschmidt S, Hilse R, van Putten JP, Gerardy-Schahn R, Unkmeir A, Frosch M (1996) Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J 15(1):192–198PubMed

14.

Chiu CP, Watts AG, Lairson LL, Gilbert M, Lim D, Wakarchuk WW, Withers SG, Strynadka NC (2004) Structural analysis of the sialyltransferase CstII from Campylobacter jejuni in complex with a substrate analog. Nat Struct Mol Biol 11(2):163–170PubMedCrossRef

15.

Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham AM, Wakarchuk WW (2002) The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 277(1):327–337PubMedCrossRef

16.

Thon V, Lau K, Yu H, Tran BK, Chen X (2011) PmST2: a novel Pasteurella multocida glycolipid alpha2-3-sialyltransferase. Glycobiology 21(9):1206–1216PubMedCrossRef

17.

Packiam M, Shell DM, Liu SV, Liu YB, McGee DJ, Srivastava R, Seal S, Rest RF (2006) Differential expression and transcriptional analysis of the alpha-2,3-sialyltransferase gene in pathogenic Neisseria spp. Infect Immun 74(5):2637–2650PubMedCrossRef

18.

Sadler F, Fox A, Neal K, Dawson M, Cartwright K, Borrow R (2003) Genetic analysis of capsular status of meningococcal carrier isolates. Epidemiol Infect 130(1):59–70PubMedCrossRef

19.

Tsai CM (2001) Molecular mimicry of host structures by lipooligosaccharides of Neisseria meningitidis: characterization of sialylated and nonsialylated lacto-N-neotetraose (Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) structures in lipooligosaccharides using monoclonal antibodies and specific lectins. Adv Exp Med Biol 491:525–542PubMedCrossRef

20.

Harvey HA, Swords WE, Apicella MA (2001) The mimicry of human glycolipids and glycosphingolipids by the lipooligosaccharides of pathogenic Neisseria and Haemophilus. J Autoimmun 16(3):257–262PubMedCrossRef

21.

Ang CW, Jacobs BC, Laman JD (2004) The Guillain–Barré syndrome: a true case of molecular mimicry. Trends Immunol 25(2):61–66PubMedCrossRef

22.

Brigham KS, Sandora TJ (2009) Neisseria meningitidis: epidemiology, treatment and prevention in adolescents. Curr Opin Pediatr 21(4):437–443PubMedCrossRef

23.

Yuki N (2007) Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 35(6):691–711PubMedCrossRef

24.

Bennetto LP, Lyons P (2004) Miller Fisher syndrome associated with Pasteurella multocida infection. J Neurol Neurosurg Psychiatry 75(12):1786–1787PubMedCrossRef

25.

Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, Ogawara K, Hattori T (2000) Haemophilus influenzae infection and Guillain–Barré syndrome. Brain 123(Pt 10):2171–2178PubMedCrossRef

26.

van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 7(10):939–950PubMedCrossRef

27.

Willison HJ, Kennedy PG (1993) Gangliosides and bacterial toxins in Guillain–Barré syndrome. J Neuroimmunol 46(1–2):105–112PubMedCrossRef

28.

Kiefer R, Kieseier BC, Stoll G, Hartung HP (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64(2):109–127PubMedCrossRef

29.

van Belkum A, van den Braak N, Godschalk P, Ang W, Jacobs B, Gilbert M, Wakarchuk W, Verbrugh H, Endtz H (2001) A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med 7(7):752–753PubMedCrossRef

30.

Godschalk PC, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J, Brochu D, Li J, Yuki N, Jacobs BC, van Belkum A, Endtz HP (2004) The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain–Barré syndrome. J Clin Invest 114(11):1659–1665PubMed

31.

Gilbert M, Godschalk PC, Karwaski MF, Ang CW, van Belkum A, Li J, Wakarchuk WW, Endtz HP (2004) Evidence for acquisition of the lipooligosaccharide biosynthesis locus in Campylobacter jejuni GB11, a strain isolated from a patient with Guillain–Barré syndrome, by horizontal exchange. Infect Immun 72(2):1162–1165PubMedCrossRef

32.

Phongsisay V, Perera VN, Fry BN (2006) Exchange of lipooligosaccharide synthesis genes creates potential Guillain–Barré syndrome-inducible strains of Campylobacter jejuni. Infect Immun 74(2):1368–1372PubMedCrossRef

33.

Haft DH, Selengut J, Mongodin EF, Nelson KE (2005) A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Comput Biol 1(6):e60PubMedCrossRef

34.

Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, Moineau S, Mojica FJ, Wolf YI, Yakunin AF, van der Oost J, Koonin EV (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9(6):467–477PubMedCrossRef

35.

Deveau H, Garneau JE, Moineau S (2010) CRISPR/Cas system and its role in phage–bacteria interactions. Annu Rev Microbiol 64:475–493PubMedCrossRef

36.

Horvath P, Barrangou R (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science (New York, N.Y.) 327(5962):167–170CrossRef

37.

Stevens J, Chen LM, Carney PJ, Garten R, Foust A, Le J, Pokorny BA, Manojkumar R, Silverman J, Devis R, Rhea K, Xu X, Bucher DJ, Paulson JC, Cox NJ, Klimov A, Donis RO (2010) Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol 84(16):8287–8299PubMedCrossRef

38.

Herrler G, Klenk HD (1987) The surface receptor is a major determinant of the cell tropism of influenza C virus. Virology 159(1):102–108PubMedCrossRef

39.

Superti F, Girmenta C, Seganti L, Orsi N (1986) Role of sialic acid in cell receptors for vesicular stomatitis virus. Acta Virol 30(1):10–18PubMed

40.

Superti F, Hauttecoeur B, Morelec MJ, Goldoni P, Bizzini B, Tsiang H (1986) Involvement of gangliosides in rabies virus infection. J Gen Virol 67(Pt 1):47–56PubMedCrossRef

41.

Gilbert J, Dahl J, Riney C, You J, Cui C, Holmes R, Lencer W, Benjamin T (2005) Ganglioside GD1a restores infectibility to mouse cells lacking functional receptors for polyomavirus. J Virol 79(1):615–618PubMedCrossRef

42.

Superti F, Donelli G (1991) Gangliosides as binding sites in SA-11 rotavirus infection of LLC-MK2 cells. J Gen Virol 72(Pt 10):2467–2474PubMedCrossRef

43.

Markwell MA, Fredman P, Svennerholm L (1984) Receptor ganglioside content of three hosts for Sendai virus. MDBK, HeLa, and MDCK cells. Biochim Biophys Acta 775(1):7–16PubMedCrossRef

44.

Sinibaldi L, Goldoni P, Pietropaolo V, Longhi C, Orsi N (1990) Involvement of gangliosides in the interaction between BK virus and Vero cells. Arch Virol 113(3–4):291–296PubMedCrossRef

45.

Yao L, Korteweg C, Hsueh W, Gu J (2008) Avian influenza receptor expression in H5N1-infected and noninfected human tissues. FASEB J 22(3):733–740PubMedCrossRef

46.

Levin BR (2010) Nasty viruses, costly plasmids, population dynamics, and the conditions for establishing and maintaining CRISPR-mediated adaptive immunity in bacteria. PLoS Genet 6(10):e1001171PubMedCrossRef

47.

Coward C, Grant AJ, Swift C, Philp J, Towler R, Heydarian M, Frost JA, Maskell DJ (2006) Phase-variable surface structures are required for infection of Campylobacter jejuni by bacteriophages. Appl Environ Microbiol 72(7):4638–4647PubMedCrossRef

48.

Connerton PL, Loc Carrillo CM, Swift C, Dillon E, Scott A, Rees CE, Dodd CE, Frost J, Connerton IF (2004) Longitudinal study of Campylobacter jejuni bacteriophages and their hosts from broiler chickens. Appl Environ Microbiol 70(7):3877–3883PubMedCrossRef

49.

Godschalk PC, Kuijf ML, Li J, St Michael F, Ang CW, Jacobs BC, Karwaski MF, Brochu D, Moterassed A, Endtz HP, van Belkum A, Gilbert M (2007) Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain–Barré and Miller Fisher syndromes. Infect Immun 75(3):1245–1254PubMedCrossRef

50.

Dzieciatkowska M, Liu X, Heikema AP, Houliston RS, van Belkum A, Schweda EK, Gilbert M, Richards JC, Li J (2008) Rapid method for sensitive screening of oligosaccharide epitopes in the lipooligosaccharide from Campylobacter jejuni strains isolated from Guillain–Barré syndrome and Miller Fisher syndrome patients. J Clin Microbiol 46(10):3429–3436PubMedCrossRef

51.

Grissa I, Vergnaud G, Pourcel C (2007) CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats. Nucleic Acids Res 35(Web Server issue):W52–W57CrossRef

52.

Wren BW, Henderson J, Ketley JM (1994) A PCR-based strategy for the rapid construction of defined bacterial deletion mutants. Biotechniques 16(6):994–996PubMed

53.

van Vliet AH, Wooldridge KG, Ketley JM (1998) Iron-responsive gene regulation in a Campylobacter jejuni fur mutant. J Bacteriol 180(20):5291–5298PubMed

54.

Kim JS, Li J, Barnes IH, Baltzegar DA, Pajaniappan M, Cullen TW, Trent MS, Burns CM, Thompson SA (2008) Role of the Campylobacter jejuni Cj1461 DNA methyltransferase in regulating virulence characteristics. J Bacteriol 190(19):6524–6529PubMedCrossRef

55.

Drummond AJ, Rambaut A (2007) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7:214PubMedCrossRef

56.

MacCallum A, Hardy SP, Everest PH (2005) Campylobacter jejuni inhibits the absorptive transport functions of Caco-2 cells and disrupts cellular tight junctions. Microbiology 151(7):2451–2458PubMedCrossRef

57.

Gaasbeek EJ, Wagenaar JA, Guilhabert MR, van Putten JP, Parker CT, van der Wal FJ (2010) Nucleases encoded by the integrated elements CJIE2 and CJIE4 inhibit natural transformation of Campylobacter jejuni. J Bacteriol 192(4):936–941PubMedCrossRef

58.

Gaasbeek EJ, Wagenaar JA, Guilhabert MR, Wösten MM, van Putten JP, van der Graaf-van Bloois L, Parker CT, van der Wal FJ (2009) A DNase encoded by integrated element CJIE1 inhibits natural transformation of Campylobacter jejuni. J Bacteriol 191(7):2296–2306PubMedCrossRef

59.

Mortensen NP, Kuijf ML, Ang CW, Schiellerup P, Krogfelt KA, Jacobs BC, van Belkum A, Endtz HP, Bergman MP (2009) Sialylation of Campylobacter jejuni lipo-oligosaccharides is associated with severe gastro-enteritis and reactive arthritis. Microbes Infect 11(12):988–994PubMedCrossRef

60.

Lindenstrauss AG, Pavlovic M, Bringmann A, Behr J, Ehrmann MA, Vogel RF (2011) Comparison of genotypic and phenotypic cluster analyses of virulence determinants and possible role of CRISPR elements towards their incidence in Enterococcus faecalis and Enterococcus faecium. Syst Appl Microbiol 34(8):553–560PubMedCrossRef

61.

Delaney NF, Balenger S, Bonneaud C, Marx CJ, Hill GE, Ferguson-Noel N, Tsai P, Rodrigo A, Edwards SV (2012) Ultrafast evolution and loss of CRISPRs following a host shift in a novel wildlife pathogen, Mycoplasma gallisepticum. PLoS Genet 8(2):e1002511PubMedCrossRef

62.

Palmer KL, Gilmore MS (2010) Multidrug-resistant enterococci lack CRISPR-cas. MBio 1(4). Pii: e00227-10

63.

Nozawa T, Furukawa N, Aikawa C, Watanabe T, Haobam B, Kurokawa K, Maruyama F, Nakagawa I (2011) CRISPR inhibition of prophage acquisition in Streptococcus pyogenes. PLoS One 6(5):e19543PubMedCrossRef

64.

Fricke WF, Mammel MK, McDermott PF, Tartera C, White DG, Leclerc JE, Ravel J, Cebula TA (2011) Comparative genomics of 28 Salmonella enterica isolates: evidence for CRISPR-mediated adaptive sublineage evolution. J Bacteriol 193(14):3556–3568PubMedCrossRef

65.

Palmer KL, Whiteley M (2011) DMS3-42: the secret to CRISPR-dependent biofilm inhibition in Pseudomonas aeruginosa. J Bacteriol 193(14):3431–2PubMedCrossRef

66.

Zegans ME, Wagner JC, Cady KC, Murphy DM, Hammond JH, O’Toole GA (2009) Interaction between bacteriophage DMS3 and host CRISPR region inhibits group behaviors of Pseudomonas aeruginosa. J Bacteriol 191(1):210–219PubMedCrossRef

67.

Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602–607PubMedCrossRef

68.

Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM (1999) Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome. Ann Neurol 45(2):168–173PubMedCrossRef

69.

Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S (2007) Preceding infections and anti-ganglioside antibodies in patients with Guillain–Barré syndrome: a single centre prospective case–control study. Clin Microbiol Infect 13(3):334–337PubMedCrossRef

70.

Perez-Rodriguez R, Haitjema C, Huang Q, Nam KH, Bernardis S, Ke A, DeLisa MP (2011) Envelope stress is a trigger of CRISPR RNA-mediated DNA silencing in Escherichia coli. Mol Microbiol 79(3):584–599PubMedCrossRef

71.

Raivio T (2011) Identifying your enemies—could envelope stress trigger microbial immunity? Mol Microbiol 79(3):557–561PubMedCrossRef

72.

Jerome JP, Bell JA, Plovanich-Jones AE, Barrick JE, Brown CT, Mansfield LS (2011) Standing genetic variation in contingency loci drives the rapid adaptation of Campylobacter jejuni to a novel host. PLoS One 6(1):e16399PubMedCrossRef

Title: A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain–Barré syndrome
Authors: R. Louwen
D. Horst-Kreft
A. G. de Boer
L. van der Graaf
G. de Knegt
M. Hamersma
A. P. Heikema
A. R. Timms
B. C. Jacobs
J. A. Wagenaar
H. P. Endtz
J. van der Oost
J. M. Wells
E. E. S. Nieuwenhuis
A. H. M. van Vliet
P. T. J. Willemsen
P. van Baarlen
A. van Belkum
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2013
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-012-1733-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia

No evidence for the effectiveness of systemic corticosteroids in acute pharyngitis, community-acquired pneumonia and acute otitis media

Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands

Paucisymptomatic infectious prostatitis as a cause of fever without an apparent origin. A series of 19 patients

Erratum to: Standard Nutrient Agar 1 as a substitute for blood-supplemented Müller–Hinton agar for antibiograms in developing countries

A delivery system of linezolid to enhance the MRSA osteomyelitis prognosis: in vivo experimental assessment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials